Vericiguat is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring intravenous therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||21/06/2021|
|Rapid review completed||15/07/2021|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of vericiguat compared with the current standard of care.|